February 4, 2025

The Evolution of Psychedelics: A Journey Through Medicine and Research

The history of psychedelics in medicine and research has evolved dramatically over the decades, moving from ancient ceremonial use to modern clinical investigations. Here's an overview:

Ancient and Traditional Use

Psychedelics have been used for thousands of years in traditional and spiritual practices across various cultures. Indigenous communities used naturally occurring psychedelics, such as psilocybin mushrooms, ayahuasca, peyote, and iboga, for religious ceremonies, healing rituals, and personal exploration. These substances were considered sacred tools for connecting with the divine and achieving expanded states of consciousness.

Early 20th Century: The Discovery Era

  • 1943: Albert Hofmann, a Swiss chemist, accidentally discovered the psychoactive properties of LSD (lysergic acid diethylamide). This marked the beginning of modern psychedelic research.
  • 1950s: Early studies explored the use of LSD, mescaline, and psilocybin in psychotherapy. Researchers like Humphry Osmond coined the term "psychedelics" (from Greek, meaning "mind manifesting") and experimented with these substances to treat mental health conditions, including depression, anxiety, and addiction.
  • Alcoholism Treatment: A groundbreaking study by Humphry Osmond and Abram Hoffer in the 1950s showed that LSD-assisted therapy helped some patients overcome alcohol dependence.
  • Psilocybin Studies: Psilocybin, the active compound in "magic mushrooms," gained attention for its therapeutic potential. Researchers began studying its effects on mood and spiritual experiences.

1960s: The Psychedelic Renaissance and Counterculture

  • Psychedelics gained immense popularity during the 1960s counterculture movement. Figures like Timothy Leary and Richard Alpert (later Ram Dass) advocated for the use of LSD and psilocybin, promoting their potential for personal and societal transformation.
  • While this period expanded awareness of psychedelics, their association with the counterculture and recreational use led to increasing concerns about misuse.
  • Governments began to crack down on psychedelics. In the United States, the Controlled Substances Act of 1970 classified LSD, psilocybin, and other psychedelics as Schedule I drugs, deemed to have no medical use and high abuse potential.

1970s-1990s: The Dormant Period

  • For decades, research into psychedelics came to a standstill due to strict regulations and stigma. The "War on Drugs" further marginalized these substances.
  • Despite the restrictions, underground therapists and researchers continued to explore their potential benefits.
  • A few notable studies on MDMA (commonly known as "ecstasy") emerged in the 1980s for its potential use in psychotherapy, particularly for trauma and PTSD, but it, too, was classified as a Schedule I drug in 1985.

2000s: The Psychedelic Resurgence

  • In the early 2000s, interest in psychedelics re-emerged as researchers advocated for a more evidence-based approach to their study. Modern brain imaging technology allowed scientists to better understand how psychedelics work in the brain.
  • Johns Hopkins University: In 2006, Johns Hopkins published a landmark study showing that psilocybin could induce mystical experiences with long-lasting positive effects on mood and behavior.
  • MAPS (Multidisciplinary Association for Psychedelic Studies): Founded in 1986, MAPS played a pivotal role in advancing research into MDMA-assisted psychotherapy for PTSD. By the 2010s, it had completed successful Phase II clinical trials.
  • Ketamine's Rise: Ketamine, a dissociative anesthetic with psychedelic properties, gained attention for its rapid-acting antidepressant effects. In 2019, the FDA approved a nasal spray version (esketamine) for treatment-resistant depression.

2010s-Present: The Modern Psychedelic Renaissance

  1. Clinical Research:
    • Universities such as Johns Hopkins, Imperial College London, and Yale began conducting rigorous studies on psychedelics.
    • Research demonstrated that psilocybin, LSD, and MDMA could be effective for conditions like depression, anxiety, PTSD, and end-of-life distress in terminally ill patients.
    • Psychedelics were shown to "reset" brain networks, particularly the default mode network (DMN), which is often overactive in mood disorders.
  2. Legal and Regulatory Changes:
    • Several cities and states in the U.S. decriminalized or legalized psilocybin for therapeutic use (e.g., Oregon in 2020).
    • The FDA designated psilocybin and MDMA as "Breakthrough Therapies," expediting their approval process.
    • Canada and Australia introduced compassionate use programs, allowing patients to access psilocybin therapy.
  3. Popularization of Ketamine:
    • Ketamine clinics proliferated globally, offering hope to patients with treatment-resistant depression and chronic pain.
    • Unlike classic psychedelics, ketamine is not a Schedule I drug, making it more accessible for off-label therapeutic use.
  4. Emerging Psychedelics:
    • Ayahuasca retreats became popular for emotional and spiritual healing.
    • Ibogaine showed promise for treating opioid addiction.
    • Research into novel psychedelics like 5-MeO-DMT (from the Sonoran Desert toad) began to grow.

Why Psychedelics Are Back in Focus

  • Mental Health Crisis: The global burden of mental health disorders, including depression, anxiety, PTSD, and addiction, has spurred the search for new treatments.
  • Mechanism of Action: Psychedelics work differently from traditional medications. They promote neuroplasticity, allowing the brain to form new connections and break out of rigid thought patterns.
  • Holistic Approach: Psychedelics often provide a sense of meaning, interconnectedness, and spiritual awakening, addressing both the psychological and existential aspects of mental illness.

The Future of Psychedelics in Medicine

  • As Phase III trials for psilocybin and MDMA progress, these substances may soon gain FDA approval for specific conditions.
  • Psychedelic-assisted therapy is becoming more integrated into mainstream medicine, with therapists and psychiatrists receiving specialized training.
  • The combination of psychedelics with other therapies, such as stellate ganglion blocks, holds promise for complex conditions like treatment-resistant mood disorders and chronic pain.

Spravato (Esketamine): A Brief Overview

Spravato is the brand name for esketamine, a nasal spray form of ketamine that was approved by the FDA in March 2019. Esketamine is a chemically similar but more potent enantiomer of ketamine, specifically developed to treat treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior. It has gained attention as a breakthrough treatment due to its rapid antidepressant effects compared to traditional oral antidepressants.Dosing Information:

  • Route of Administration: Intranasal.
  • Induction Phase: 
    • Administered twice weekly for the first 4 weeks.
  • Maintenance Phase: 
    • Administered once weekly or every two weeks, depending on the patient's response and needs.
  • Dosage Strengths: 
    • The initial dose is 56 mg, followed by 56 mg or 84 mg in subsequent treatments.
  • Spravato is always administered under medical supervision in a healthcare setting due to the risk of side effects such as sedation, dissociation, and increased blood pressure.

Why Was FDA Approval Controversial?

‍The approval of Spravato by the FDA sparked debates in the medical community for several reasons:

1. Clinical Trial Limitations:

  • Efficacy Concerns: Out of three short-term clinical trials conducted for treatment-resistant depression, only one showed statistically significant efficacy compared to placebo.
  • Critics argued that the evidence supporting Spravato's antidepressant effects was inconsistent and insufficient to justify approval.
  • Long-term safety data was limited at the time of approval.

2. Placebo Effect in Studies:

  • Due to the dissociative effects of esketamine, participants could often tell whether they received the drug or a placebo, which may have biased results.
  • High Cost:
    • Spravato is significantly more expensive than traditional antidepressants or even intravenous ketamine, making it less accessible to some patients.

3. Safety Concerns:

  • Spravato comes with a black box warning for: 
    • Sedation
    • Dissociation
    • Suicidal thoughts and behaviors
  • It must be administered in certified healthcare settings under strict monitoring, adding logistical challenges for both patients and providers.

4. Fast-Tracking Approval:

  • Esketamine was granted FDA fast-track approval under pressure to address the unmet needs of patients with treatment-resistant depression. Critics argued that the fast-track process compromised the rigor of evidence-based review.

Current Use and Impact:

‍Despite the controversies, Spravato represents a promising treatment for patients who have not responded to conventional therapies. Its rapid onset of action, often within hours, sets it apart from traditional antidepressants, which can take weeks to work. However, its high cost, limited access, and strict monitoring requirements have limited widespread adoption.

In summary, the history of psychedelics in medicine has come full circle—from ancient traditions to groundbreaking research—offering new hope for some of the most challenging mental health and pain conditions. The future of psychedelics is bright, with science, regulation, and society converging to unlock their full potential.

At StrIVeMD Wellness and Ketamine in Illinois (Chicago, Skokie, St. Charles, Champaign), Frisco/Dallas, and now Dublin/Columbus Ohio, we are helping to transform lives with compassionate care and innovative treatments for complex conditions, including as an adjunt to helping with seasonal affective disorder. IV Ketamine therapy/IV ketamine infusions as well as ultrasound-guided stellate ganglion blocks to help with depression (including those who get depressed from social media), as well as PTSD, anxiety, and other complex treatment resistant mental health disorders.  With a team comprised of physicians board-certified in adult and pediatric anesthesiology, pain medicine, and functional medicine, advanced practice nurses and certified registered nurse anesthetists (CRNA), we are the most comprehensive team from the nation’s best medical institutions to take care of patients of any age including adolescents and geriatric patients.  We work with your mental health provider to ensure safety and effectiveness of our program. If you or someone has severe rumination or mental health disease that is worsening, or fighting a chronic medical condition, please consider potentially transformative solutions for mental health challenges or chronic pain that have resisted conventional treatments.  In the meantime, if you have any questions, please feel free to email us at info@strivemdwellness.com.  

‍Contact Us Today

‍If you or someone you know is struggling or struggles with seasonal affective disorder, reach out to StriveMD Wellness & Ketamine to learn more about how our treatments can help.  With the right support and care, it is possible to regain control over your mental health and find joy even in the darkest times.Contact us at:Phone number: Ohio (614) 992-5484, Illinois (847) 213-0990, Texas (469) 656-4999Email: info@strivemdwellness.comWebsite: www.strivemdwellness.comRediscover your peace of mind and take the first step towards healing with StrIVeMD Wellness & Ketamine.